After more than a decade of facing barriers, direct-to-patient (DTP) shipment of investigational products is coming into its own now that pandemic conditions have prompted solutions to major transportation problems. Sites and sponsors now have more DTP options, but there are still some kinks to work out and regulatory guidance needed.